Sagent Pharmaceuticals Inc (SGNT)

21.73
0.01 0.05
NASDAQ : Health Care
Prev Close 21.74
Open 21.73
Day Low/High 21.73 / 21.75
52 Wk Low/High 10.55 / 21.88
Volume 544.00K
Avg Volume 919.10K
Exchange NASDAQ
Shares Outstanding 32.91M
Market Cap 715.80M
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Changing Landscape for Generic-Drug Makers Creates Opportunities

Changing Landscape for Generic-Drug Makers Creates Opportunities

The generic-drug industry has undergone a flurry of acquisition activity over the past 18 months, highlighted by the long-anticipated but only recent closing of Teva Pharmaceutical's purchase of Allergan's generics.

Shepard Vision, Inc., A Wholly-Owned Subsidiary Of Nichi-Iko Pharmaceutical Co., Ltd, Commences All-Cash Tender Offer Of $21.75 Net Per Share To Acquire All Outstanding Shares Of Sagent Pharmaceuticals, Inc.

Shepard Vision, Inc., A Wholly-Owned Subsidiary Of Nichi-Iko Pharmaceutical Co., Ltd, Commences All-Cash Tender Offer Of $21.75 Net Per Share To Acquire All Outstanding Shares Of Sagent Pharmaceuticals, Inc.

Shepard Vision, Inc., a Delaware corporation (the "Purchaser") and a wholly-owned subsidiary of Nichi-Iko Pharmaceutical Co.

Sapiens Names Andre M. Boisvert Chairman Of Sapiens DECISION Board Of Directors

Sapiens Names Andre M. Boisvert Chairman Of Sapiens DECISION Board Of Directors

The proven software industry executive's vision and extensive network will assist the Sapiens DECISION leadership team on strategic investment decisions and the future direction of the business

Short Interest In Sagent Pharmaceuticals Drops 33.5%

Short Interest In Sagent Pharmaceuticals Drops 33.5%

The most recent short interest data has been released for the 07/15/2016 settlement date, which shows a 791,641 share decrease in total short interest for Sagent Pharmaceuticals Inc , to 1,570,672, a decrease of 33.51% since 06/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

INVESTOR ALERT: The Law Offices Of Vincent Wong Launches An Investigation Of The Board Of Directors Of Sagent Pharmaceuticals, Inc. Concerning The Sale Of The Company To Nichi-Iko Pharmaceutical Co., Ltd.

INVESTOR ALERT: The Law Offices Of Vincent Wong Launches An Investigation Of The Board Of Directors Of Sagent Pharmaceuticals, Inc. Concerning The Sale Of The Company To Nichi-Iko Pharmaceutical Co., Ltd.

The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Sagent Pharmaceuticals, Inc.

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Sagent Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Sagent Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Sagent...

INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Whether The Sale Of Sagent Pharmaceuticals, Inc. To Nichi-Iko Pharmaceutical Co., Ltd. For $21.75 Per Share Is Fair To Shareholders

INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Whether The Sale Of Sagent Pharmaceuticals, Inc. To Nichi-Iko Pharmaceutical Co., Ltd. For $21.75 Per Share Is Fair To Shareholders

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Sagent Pharmaceuticals, Inc.

SAGENT SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Sagent Pharmaceuticals, Inc. (SGNT) Over the Proposed Sale of the Company to Nichi-Iko Pharmaceutical Co., Ltd.

SAGENT SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Sagent Pharmaceuticals, Inc. (SGNT) Over the Proposed Sale of the Company to Nichi-Iko Pharmaceutical Co., Ltd.

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Sagent Pharmaceuticals, Inc.

INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Into The Sale Of Sagent Pharmaceuticals, Inc. To Nichi-Iko Pharmaceutical Co., Ltd. For $21.75 Per Share Is Fair To Shareholders -- SGNT

INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Into The Sale Of Sagent Pharmaceuticals, Inc. To Nichi-Iko Pharmaceutical Co., Ltd. For $21.75 Per Share Is Fair To Shareholders -- SGNT

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Sagent Pharmaceuticals, Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMRC, ATTO, CODI, PEB, SGNT, TCRD, TEO, TSLX, USBI, VMI Downgrades: EMXX Initiations: AEUA, CABO Read on to get TheStreet Quant Ratings' detailed report:

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Sagent Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Sagent Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Sagent...

Sagent Pharmaceuticals (SGNT) Soared Today on Nichi-Iko Deal

Sagent Pharmaceuticals (SGNT) Soared Today on Nichi-Iko Deal

Sagent Pharmaceuticals (SGNT) stock closed sharply higher today after agreeing to be purchased by Nichi-Iko for $736 million.

3 Stocks You Might Want to Sell Now

3 Stocks You Might Want to Sell Now

These three stocks are seeing big trading volume today, but that doesn't necessarily mean you want to buy them.

Sagent Pharmaceuticals, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Merger With Nichi-Iko Pharmaceutical Co., Ltd.

Sagent Pharmaceuticals, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Merger With Nichi-Iko Pharmaceutical Co., Ltd.

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Sagent...

Nichi-Iko Pharmaceutical Co., Ltd To Acquire Sagent Pharmaceuticals For $21.75 Per Share In All Cash Transaction

Nichi-Iko Pharmaceutical Co., Ltd To Acquire Sagent Pharmaceuticals For $21.75 Per Share In All Cash Transaction

Nichi-Iko Pharmaceutical Co., Ltd (TSE:4541) and Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals Acquires Product Portfolio From Teva Pharmaceutical Industries Ltd.

Sagent Pharmaceuticals Acquires Product Portfolio From Teva Pharmaceutical Industries Ltd.

Products Include Propofol for the U.S. Market; Positive Next Step in 'Triple E' Growth Strategy

Sagent Pharmaceuticals (SGNT) Flagged As Strong On High Volume

Sagent Pharmaceuticals (SGNT) Flagged As Strong On High Volume

Trade-Ideas LLC identified Sagent Pharmaceuticals (SGNT) as a strong on high relative volume candidate

Commit To Purchase Sagent Pharmaceuticals At $10, Earn 7.2% Annualized Using Options

Commit To Purchase Sagent Pharmaceuticals At $10, Earn 7.2% Annualized Using Options

Investors considering a purchase of Sagent Pharmaceuticals Inc stock, but tentative about paying the going market price of $13.94/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2017 put at the $10 strike, which has a bid at the time of this writing of 45 cents.